Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Acronyms Zoster-048
- Sponsors GlaxoSmithKline; GSK
- 27 Feb 2020 Results from post-hoc analyses on the correlation between humoral and CMI responses and polyfunctional CD4 T-cell responses published in the Journal of Infectious Diseases
- 07 Oct 2018 Results presented at the IDWeek 2018
- 08 Oct 2017 Primary endpoint (Anti-glycoprotein E (Anti-gE) Antibody (Ab) Concentrations-non-inferiority) has been met, according to results presented at the IDWeek 2017.